- Conditions
- Uterine Cancer
- Interventions
- Imatinib Mesylate, Paclitaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 83
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Copanlisib, Radiologic Examination
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leptomeningeal Metastasis
- Interventions
- 186RNL
- Drug
- Lead sponsor
- Cerenome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- lenvatinib, everolimus
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Lung Cancer, Small Cell
- Interventions
- topotecan
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 6
- States / cities
- Lebanon, New Hampshire • The Bronx, New York • Philadelphia, Pennsylvania + 3 more
- Conditions
- Glioma, Glioma (Any Grade) in the Brain, Glioblastom WHO Grade 4, Glioblastoma, Glioblastoma (GBM), Grade III Astrocytoma, Grade II Glioma, Grade IV Astrocytoma, Grade IV Glioma, Grade III Glioma
- Interventions
- Connectome MRI, Neuropsychological testing
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
- Interventions
- Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Tumor, Metastatic Colorectal Cancer
- Interventions
- dasatinib, bevacizumab, Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- Herbert Hurwitz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Durham, North Carolina
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Interventions
- LY3410738, Gemcitabine, Cisplatin, Durvalumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
- Conditions
- Oropharyngeal Carcinoma
- Interventions
- 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
- Diagnostic Test · Combination Product · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 521 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 134
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more
- Conditions
- Hormone Receptor Positive Breast Cancer
- Interventions
- faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 12
- States / cities
- Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more
- Conditions
- Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Primary Liver Cancer, Metastatic Liver Cancer From Any Cancer Site
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Regorafenib 40 MG
- Drug
- Lead sponsor
- SC Liver Research Consortium, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more
- Conditions
- Lung Cancer
- Interventions
- sorafenib
- Drug
- Lead sponsor
- Swedish Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
- Interventions
- fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
- Radiation · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 754 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Azacitidine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Solid Tumors), Cancer (With or Without Metastasis), Cancer - Ovarian, Cancer Abdomen, Cancer (Advanced Stage)
- Interventions
- Not listed
- Lead sponsor
- WellSpan Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Chambersburg, Pennsylvania • Ephrata, Pennsylvania • Gettysburg, Pennsylvania + 2 more
- Conditions
- A Diagnosis of Any Hematologic or Solid Malignancy
- Interventions
- Daily SMS text messaging
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- PD0332991, Paclitaxel
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Burbank, California • Duarte, California + 47 more
- Conditions
- Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
- Interventions
- Enbrel
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- San Antonio, Texas